To include your compound in the COVID-19 Resource Center, submit it here.

BerGenBio reports Phase I/II data for BGB324

BerGenBio ASA (OSE:BGBIO) said daily 200 mg bemcentinib (BGB324) plus EGFR inhibitor Tarceva erlotinib met the initial efficacy endpoint in the first stage of the Phase II

Read the full 279 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE